BGNE:NSD-BeiGene, Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 302.00

Change

+9.25 (+3.16)%

Market Cap

USD 27.46B

Volume

0.18M

Average Target Price

USD 316.67 (+4.86%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BGNE

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.79 (+1.50%)

USD0.03B
CHB Global X China Biotech In.. 0.00 % 0.67 %

+0.53 (+3.09%)

N/A
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.72 (+2.46%)

USD0.05B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.24 (+2.73%)

USD0.29B
BIGT:LSE L&G Pharma Breakthrou.. 0.00 % 0.75 %

+15.45 (+1.74%)

USD0.03B
ETLI:F L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.17 (+1.69%)

USD0.03B
ETLI:XETRA L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.17 (+1.63%)

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.88% 71% C- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.88% 71% C- 65% D
Trailing 12 Months  
Capital Gain 87.95% 72% C- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.95% 72% C- 65% D
Trailing 5 Years  
Capital Gain 909.70% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 909.70% 95% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 93.27% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.27% 88% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 107.65% 24% F 13% F
Risk Adjusted Return 86.64% 97% A+ 90% A-
Market Capitalization 27.46B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.19 31% F 24% F
Price / Cash Flow Ratio -21.39 81% B- 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -66.03% 47% F 18% F
Return on Invested Capital -58.67% 43% F 14% F
Return on Assets -28.73% 45% F 13% F
Debt to Equity Ratio 4.75% 65% D 81% B-
Technical Ratios  
Short Ratio 8.32 18% F 8% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.92 72% C- 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector